آخر تحديث: أغسطس 17, 2026
علاج التوحد بالخلايا الجذعية
عمومًا, parents notice signs of Autism very early before age 2 أو 3. Mostly, motor milestones develop normally but delays can be observed. Parents might notice delays in speech and interactions or sometimes the speech develops but regresses thereafter.
As brain functioning is heavily involved in توحد, scientists and researchers have started looking at regenerative therapy using الخلايا الجذعية as potential مُعَالَجَة ل توحد.
Recent studies have indicated that the lack of oxygen supply to the brain during or after birth and immune deregulation are the two important factors associated with Autism . These factors may result in decreased functioning of the brain or irregularities in the brain. This can cause an overarching imbalance in the brain which could get manifested as the carious symptoms of Autism.
الخلايا الجذعية have the capability to multiply into many cells and form specialized cells different from the mother cell. This regeneration of cells can help in repairing the damaged brain tissue. Stem cells have the potential to repair the affected neural tissue at the molecular, structural and functional level. They are known to address the core of neuropathology of Autism with the help of their unique paracrine regulatory functions that are capable of regulating cell differentiation, tissue and organ repair, neurotrophic and anti-inflammatory actions in the recipient.
Results of the first phase of a clinical research regarding Autism therapy by using stem cells
And in early April 2017, Duke University officially published t results of the first phase of a البحوث السريرية on the safety of Autism stem cells treatment . It was 25 children of both sexes aged 2 ل 5 سنين. Efficiency was registered by parents’ interviews and a number of clinical tests. It is reported that in more than 60% of the subjects there was a improvements of autism spectrum disorders (اضطراب طيف التوحد) . Physicians start further research – FDA approved double-blind, placebo-controlled study with 165 autistic children between the ages of 2 و 8 starts.
CNN showed a video of one family who took part in the trial and saw encouraging changes in her little daughter
https://edition.cnn.com/2017/04/05/health/autism-cord-blood-stem-cells-duke-study/index.html
خلاصة:
مصدر – الطب الترجمي للخلايا الجذعية 2017;6:1332–1339
Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (اضطراب طيف التوحد) are needed. We hypothesized that umbilical cord blood‐derived cell therapies may have potential in alleviating ASD symptoms by modulating inflammatory processes in the brain. Accordingly, we conducted a phase I, open‐label trial to assess the safety and feasibility of a single intravenous infusion of autologous umbilical cord blood, as well as sensitivity to change in several ASD assessment tools, to determine suitable endpoints for future trials. Twenty‐five children, median age 4.6 سنين (range 2.26–5.97), with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit, were enrolled. Children were evaluated with a battery of behavioral and functional tests immediately prior to cord blood infusion (خط الأساس) و 6 و 12 months later. Assessment of adverse events across the 12‐month period indicated that the treatment was safe and well tolerated. Significant improvements in children’s behavior were observed on parent‐report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye‐tracking measures of children’s attention to social stimuli, indicating that these measures may be useful endpoints in future studies. Behavioral improvements were observed during the first 6 months after infusion and were greater in children with higher baseline nonverbal intelligence quotients. These data will serve as the basis for future studies to determine the efficacy of umbilical cord blood infusions in children with ASD.
مصدر – الطب الترجمي للخلايا الجذعية 2017;6:1332–1339
واتساب: +447778936902 , +33745637397, +34670491885
بريد إلكتروني: [email protected]
مراجعة الحالة العلمية
هل ترغب في فهم ما إذا كانت البرامج السريرية الحالية, التطورات البحثية الأخيرة, أو قد تكون النهج الناشئة ذات الصلة بحالتك الفردية?
شارك سؤالك مع فريق البحث العلمي لدينا واستقبله المعلومات التي تركز على مجالات البحث الحالية التي قد تكون ذات الصلة بحالتك.
- مراجعة المعلومات التي تقدمها
- البحوث ذات الصلة ومعلومات البرنامج السريري
- استجابة واضحة تركز على حالتك
لا التزام. سيتم مراجعة سؤالك بسرية.
المعلومات التعليمية والبحثية فقط. هذه الخدمة لا تشكل نصيحة طبية, تشخبص, روشتة, أو شخصية توصية العلاج.
